Clinical Trial Update: Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of anti-PD-1 antibody with autologous dendritic cells and natural killer cells for digestive carcinoma; current …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive Carcinoma
• Gastrointestinal Tumours

Drugs mentioned

• DC-Cell (dendritic cell therapy)
• NK Cells (natural killer cell therapy)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: China Medical University, China | Conditions: PD-1 Antibody, DC-Cell | Phase 2 | Status: UNKNOWN